Treatment With Anti-Tumor Necrosis Factor Biologic Agents in Human T Lymphotropic Virus Type I-Positive Patients With Rheumatoid Arthritis

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

(2014) Yoshiya Tanaka et al.   Modern Rheumatology

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

(2014) Hideto Kameda et al.   Modern Rheumatology

Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series

(2013) Kunihiko Umekita et al.   Modern Rheumatology

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review

(2012) R. J. Moots et al.   RHEUMATOLOGY

Current prevalence of HTLV-1 in Japan as determined by screening of blood donors

(2011) Masahiro Satake et al.   JOURNAL OF MEDICAL VIROLOGY

Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

(2011) H. KAMEDA et al.   JOURNAL OF RHEUMATOLOGY